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 ABSTRACT 
Osteogenesis imperfecta (OI) is a genetic disease of Type I collagen and collagen-
associated pathways that results in brittle bone behavior characterized by fracture and reduced 
mechanical properties. Based on previous work in our laboratory showing that raloxifene (RAL) 
can significantly improve bone mechanical properties through non-cellular mechanisms, we 
hypothesized that raloxifene would improve the mechanical properties of OI bone. In experiment 
1, tibiae from female wild type (WT) and homozygous oim mice were subjected to in vitro soaking 
in RAL followed by mechanical tests. RAL soaking resulted in significantly higher post-yield 
displacement (+75% in WT, +472% in oim; p<0.004), with no effect on ultimate load or stiffness, 
in both WT and oim animals. In experiment 2, eight-week old WT and oim male mice were treated 
for eight weeks with saline vehicle (VEH) or RAL. Endpoint measures included assessment of in 
vivo skeletal fractures, bone density/geometry and mechanical properties. In vivo skeletal 
fractures of the femora, assessed by micro CT imaging, were significantly lower in oim-RAL (20%) 
compared to oim-VEH (48%, p=0.047). RAL led to significantly higher DXA-based BMD (p<0.01) 
and CT-based trabecular BV/TV in both WT and oim animals compared to those treated with 
VEH. Fracture toughness of the femora was lower in oim mice compared to WT and improved 
with RAL in both genotypes. These results suggest that raloxifene reduces the incidence of 
fracture in this mouse model of oim. Furthermore, they suggest that raloxifene’s effects may be 
the result of both cellular (increased bone mass) and non-cellular (presumably changes in 
hydration) mechanisms, raising the possibility of using raloxifene, or related compounds, as a 
new approach for treating bone fragility associated with OI. 
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INTRODUCTION 
Osteogenesis Imperfecta (OI), is a heritable disorder of connective tissues caused by 
mutations in Type I collagen or other genes in collagen associated pathways [1,2]. Over 1500 
independent alterations in the primary structure of OI collagen have been identified leading to a 
wide spectrum of clinical severities. The dominant OI phenotype is in bone and is typified by low 
energy fracture, leading to the term “brittle bone” disease. OI compromises the three main 
components that influence bones’ mechanical properties - bone mass, geometry, and bone quality 
[3-8]. The complex changes across multiple-hierarchical levels present unique challenges for 
treatment.  
Several mouse models of OI exist [9]. The Osteogenesis Imperfecta murine (oim) model 
was described in 1993 [10], and is the most characterized of these models. This mouse has a 
single base pair mutation in the 2 gene causing a frame shift of the final 48 amino acids at the 
C-terminus of the propeptide. This shift changes the collagen amino acid sequence and adds an 
extra residue. The resulting 2 chains are non-functional as they can no longer associate with 1 
chains [1]. Homotrimeric 1 collagen molecules result, accumulating in the extracellular matrix 
and disrupting proper fibril assembly. 2 gene mutations are rare in humans, but the homozygous 
oim mouse is considered a good phenotypic model of human type III OI, as it results in a moderate 
to severe OI characterized by spontaneous fractures and limb deformities [11]. 
Current pharmacological interventions for OI incompletely normalize mechanical 
properties. For many forms of OI, pharmacological treatment with bisphosphonates has proven 
effective in reducing, but not eliminating fracture as assessed with cross sectional [12,13] and 
controlled clinical trials [14-19].  When trials were examined with meta-analysis it was clear that 
a treatment gap remains as clear evidence of improved clinical status is lacking  [20].   
-Page 4 - 
Animal data (using both the oim and Brtl/+ animal models) have documented that 
treatment with bisphosphonates can recover bone mass and architecture to near wild-type levels, 
yet whole-bone mechanical properties remain compromised compared to normal bone [21-23]. 
This is likely due to the lack of positive effect of bisphosphonates on the quality of the bone tissue 
[24]. More recent data with anabolic treatment (anti-sclerostin antibody) have also shown positive 
results in animal models (specifically the Brtl mouse), but again, the data point to drug-induced 
effects on bone mass, but not quality [25]. Thus, current approaches have been able to enhance 
bone mass in the setting of OI but have failed to positively affect bone quality. 
Raloxifene, a selective estrogen receptor modulator (SERM), is an FDA-approved agent 
used to reduce fracture risk in osteoporotic patients [26,27]. SERMs are utilized as they effectively 
antagonize estrogen receptors in bone cells (reducing osteoclast development) while not affecting 
other estrogenic tissues.  Recent work has shown that raloxifene, both in vivo and in vitro, 
increases bone through an additional mechanism, specifically through non-cellular effects that 
result in increased skeletal bound water [28,29]. The raloxifene-induced alterations in bound water 
are associated with positive effects on bone mechanical properties [28,29] and these benefits 
have recently been shown to extend to disease models with compromised bone quality [30]. 
Therefore, the goal of this study was to test the hypothesis that raloxifene could produce beneficial 
effects on bone mechanical properties in a mouse model of OI.  
 
RESULTS 
Experiment #1  
 Paired tibiae from WT and oim mice were mechanically tested to failure in 4-point bending 
after ex vivo incubation in either PBS or RAL. Force (yield and ultimate), displacement (yield, 
post-yield and total), stiffness, and work (yield, post-yield, and total) were all significantly lower 
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with oim (Table 1). RAL soaking had a significant main effect, producing higher post-yield 
displacement (p<0.0001), and total displacement (p<0.0001) (Table 1 and Figure 1). This 
indicates that RAL is able to impart benefits to mechanical properties through non-cellular 
mechanisms in both WT and oim mouse bones. For properties that had a significant interaction 
effect, significant differences (p<0.001 for all) in yield force, displacement to yield, stiffness, and 
work to yield were observed with RAL soaking in the WT group, but not in the oim group. Total 
work was significantly different with RAL treatment in both the WT and oim groups. 
 
Figure 1. Ex-vivo soaking of osteogenesis imperfecta bones in raloxifene leads to significantly higher mechanical 
properties.  In this 2x2 study design, both post-yield displacement and total displacement had significant main effects 
of disease and treatment (each p < 0.05) indicating that oim bones were lower than WT for both properties and that 
raloxifene exposure led to significantly higher properties in both wild-type and oim animals. Values are presented as 
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mean  standard deviation. WT- wild-type; oim-osteogenesis imperfecta; PBS-phosphate buffered saline; RAL-
raloxifene.  
 
Table 1: Mechanical properties from 4-point bending of raloxifene-soaked tibiae 
 
 
WT OIM  
Control (n=15) Raloxifene (n=15) Control (n=9) Raloxifene (n=9) 
Yield Force (N) #  18.40 ± 1.25 a b 22.17 ± 2.01 a d 6.77 ± 1.35 b 6.96 ± 1.64 d 
Ultimate Force (N) *+ 23.44 ± 2.92 24.65 ± 1.79 7.28 ± 1.64 8.00 ± 1.65 
Stiffness (N/mm) #  105.2 ± 10.17 a b 94.09 ± 12.42 a d 35.27 ± 35.27 b 36.37 ± 7.27 d 
Deformation to Yield (m) #  213 ± 16 a 272 ± 33 a d 228 ± 23 224  ± 18 d 
Postyield Deformation (m) *+ 398 ± 178 675 ± 192 28 ± 35 163 ± 130 
Total Deformation (m) *+ 611 ± 186  947 ± 210 256 ± 46 387 ± 137 
Work to Yield (mJ) #  2.06 ± 0.20 a b 3.19 ± 0.60 a d 0.83 ± 0.21 b 0.86 ± 0.25 d 
Postyield Work (mJ) *+ 8.12 ± 3.05 14.56 ± 3.96 0.21 ± 0.26 1.18 ± 0.80 
Work to Failure (mJ) #  10.18 ± 3.16 a b 17.75 ± 4.22 a d 1.04 ± 0.39 b c 2.04 ± 0.86 c d 
Values are presented as mean ± standard deviation.  WT- wild-type; oim-osteogenesis imperfecta. In the property column, * 
indicates a main effect of disease, + indicates a main effect of treatment, and # indicates an interaction term (p<0.05). For 
parameters with an interaction term, a posthoc pairwise t-test with Bonferroni correction was used (p<0.0125). a indicates a 
significant difference between WT-Control and WT-Raloxifene, b indicates a significant difference between WT-Control and 
oim-Control, c indicates a significant difference between oim-Control and oim-Raloxifene, and d indicates a significant 
difference between WT-Raloxifene and oim-Raloxifene. 
Experiment #2  
Fracture Assessment 
 There were no fractures in the WT animals. In oim vehicle-treated animals, 48% of the 
femurs were fractured, while in the oim raloxifene-treated animals the percentage of fractures was 
significantly lower (20%, p=0.047) (Figure 2). 
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Figure 2. In vivo treatment with raloxifene lead to significantly fewer femoral fractures in animals with osteogenesis 
imperfecta.  In vehicle-treated animals, 48% of the femora (13 of 27) were fractured (one bone was missing from the 
analysis).  In raloxifene-treated animals, 20% of the femora (6 of 30) were fractured.  This represents a significant (* p 
< 0.05) 58% reduction in the number of in vivo fractures. A representative projection image of a fractured bone from 
an oim animals is depicted. 
 
DXA 
 DXA-based BMD in the oim mice was significantly lower for the whole body, L4-L5 
vertebrae, and femur compared to WT (p<0.001 each). RAL treatment resulted in higher BMD in 
both genotypes as indicated by a significantly higher BMD in the whole body (WT: +4%, oim: 
+7%; p=0.0187) and femur (WT: +10%, oim: +13%; p=0.0066). Oim animals treated with RAL 
remained lower than WT controls for all sites (Figure 3).  
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Figure 3. In vivo treatment with raloxifene resulted in higher areal bone mineral density in animals with osteogenesis 
imperfecta.  Following 8 weeks of treatment, total body, lumber spine, and femoral bone mineral density (BMD) from 
dual-energy x-ray absorptiometry was assessed. In this 2x2 study design, all three measures had significant main 
effects of disease (p < 0.05), while whole body and femur also had main effects of treatment (p<0.05), indicating that 
oim bones were lower than WT and that raloxifene exposure led to significantly higher properties in both wild-type 
and oim animals.  Values are presented as mean ± standard deviation.  WT- wild-type; oim-osteogenesis imperfecta; 
RAL-raloxifene. 
uCT 
 Within the cancellous ROI, bone volume per tissue volume (BV/TV), trabecular number 
(Tb.N), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and bone mineral density (BMD) 
were all significantly worse in the oim animals compared to WT (p<0.0001 for all) (Table 2). With 
raloxifene treatment, BV/TV was significantly higher in both genotypes (WT: +5%, oim: +68%; 
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p=0.0381). These effects on BV/TV were mainly driven by differences in Tb.Th. In addition, BMD 
was significantly higher in RAL-treated animals (WT: +2%, oim: +6%; p<0.0001). 
 
 
Table 2: Cancellous architecture in the distal femoral metaphysis 
 
WT OIM 
Control (n=8) Raloxifene (n=8) Control (n=10) Raloxifene (n=12) 
BV/TV (%)*+ 21.19 ± 2.97 22.16 ± 3.97 4.88 ± 3.01 8.20 ± 3.00 
Trabecular thickness (m) *+ 0.0669 ± 0.0023 0.0702 ± 0.0028 0.0544 ± 0.0036 0.0611 ± 0.0031 
Trabecular separation (mm) * 0.189 ± 0.014 0.186 ± 0.013 0.364 ± 0.126 0.300 ± 0.068 
Trabecular number (1/mm) * 3.160 ± 0.401 3.143 ± 0.459 0.880 ± 0.518 1.331 ± 0.459 
Tissue Mineral Density (g/cm3) *+ 0.836 ± 0.015 0.855 ± 0.019 0.768 ± 0.025 0.814 ± 0.027 
Values are presented as mean ± standard deviation. WT- wild-type; oim-osteogenesis imperfecta; BV/TV 
– bone volume/tissue volume. In the property column, * indicates a main effect of disease and + indicates 
a main effect of treatment. 
 
 Analysis of a standard cortical ROI indicated that oim mice had significantly lower total 
cross sectional area (p<0.001), cortical area (p<0.001), cortical thickness (p<0.001), periosteal 
and endocortical bone perimeters (p<0.001 and p=0.002, respectively), and moment of inertia in 
the maximum and minimum directions (p<0.001 for both) versus WT (Table 3). RAL treatment 
resulted in significantly higher cortical thickness in both genotypes (p=0.0185).  
 
Table 3: Cortical geometry at the femoral mid-diaphysis 
 
WT OIM  
Control (n=8) Raloxifene (n=8) Control (n=10) Raloxifene (n=12) 
Cross Sectional Area (mm2)  * 1.992 ± 0.189 1.985 ± 0.225 1.427 ± 0.211 1.380 ± 0.129 
Marrow Area (mm2) 0.867 ± 0.132 0.794 ± 0.101 0.806 ± 0.170 0.726 ± 0.111 
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Cortical Area (mm2) * 1.126 ± 0.105 1.191 ± 0.133 0.622 ± 0.111 0.654 ± 0.090 
Cortical Thickness (mm) * + 0.273 ± 0.022 0.293 ± 0.017 0.171 ± 0.026 0.184 ± 0.027 
Periosteal Perimeter (mm) * 5.784 ± 0.261 5.768 ± 0.290 4.981 ± 0.352 4.967 ± 0.272 
Endocortical Perimeter (mm)* 4.274 ± 0.330 4.086 ± 0.277 3.863 ± 0.371 3.715 ± 0.263 
Imax (mm4) * 0.375 ± 0.078 0.392 ± 0.085 0.146 ± 0.050 0.152 ± 0.030 
Imin (mm4)  * 0.175 ± 0.027 0.179 ± 0.040 0.086 ± 0.022 0.081 ± 0.020 
Tissue Mineral Density (g/cm3) 1.271 ± 0.016 1.278 ± 0.018 1.281 ± 0.032 1.284 ± 0.036 
Values are presented as mean ± standard deviation. WT- wild-type; oim-osteogenesis imperfecta; Imax-
Maximum moment of inertia; Imin-Minimum moment of inertia.  In the property column, * indicates a main 
effect of disease and + indicates a main effect of treatment. 
 
Whole Bone Mechanical Testing 
 At both the structural and tissue level, oim bones exhibited significantly lower mechanical 
properties compared to WT (p<0.024 for all properties) (Table 4). There were no significant effects 
of raloxifene treatment for any parameter.  
 
 
Table 4: Tibial mechanical properties from 4-point bending 
 
WT OIM 
Control (n=7) Raloxifene (n=8) Control (n=8) Raloxifene (n=7) 
Yield Force (N) * 24.35 ± 4.75 27.66 ± 3.99 8.97 ± 2.57 8.79 ± 3.02 
Ultimate Force (N) * 27.29 ± 3.87 28.62 ± 4.48 10.61 ± 2.95 10.87 ± 3.53 
Displacement to Yield (µm) * 184 ± 28 209 ± 18 175 ± 23 169 ± 21 
Postyield Displacement (µm) * 314 ± 113 263 ± 160 102 ± 55 97 ± 18 
Total Displacement (µm) * 498 ± 132 471 ± 170 277 ± 69 266 ± 26 
Stiffness (N/mm) * 137.78 ± 13.24 141.26 ± 14.93 53.30 ± 20.38 55.24 ± 22.96 
Work to Yield (mJ) * 2.38 ± 0.82 2.98 ± 0.62 0.80 ± 0.23 0.77 ± 0.27 
Total Work (mJ) * 8.81 ± 2.96 7.88 ± 3.58 1.67 ± 0.40 1.74 ± 0.60 
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Yield Stress (MPa) * 127.47 ± 33.29 160.61 ± 26.97 83.44 ± 17.83 79.32 ± 18.20 
Ultimate Stress (MPa) * 141.64 ± 27.35 166.00 ± 28.60 98.65 ± 20.20 98.74 ± 23.88 
Strain to Yield (µ) * 13699 ± 2730 15814 ± 2902 10456 ± 2494 11214 ± 1873 
Total Strain (µ) * 37290 ± 11853 36561 ± 15556 16269 ± 3909 17704 ± 2953 
Modulus (GPa) * 9.60 ± 1.14 11.01 ± 1.81 8.26 ± 2.65 7.60 ± 2.27 
Resilience (MPa) * 0.95 ± 0.42 1.33 ± 0.43 0.45 ± 0.13 0.46 ± 0.13 
Toughness (MPa) * 3.47 ± 1.37 3.55 ± 1.92 0.95 ± 0.30 1.05 ± 0.34 
Values are presented as mean ± standard deviation. WT- wild-type; oim-osteogenesis 
imperfecta. In the property column, * indicates a main effect of disease and + indicates 
a main effect of treatment. 
 
Fracture Toughness Testing 
 Oim mice had significantly lower stress intensity factors at yielding (Kinit), maximum load 
(Kmax load) and failure (Kinst) compared to WT (p<0.0001). Treatment with RAL led to a significantly 
higher Kmax load (p=0.0458) in both genotypes (+8.43% in WT and +4.19% in oim; Table 5). 
 
Table 5: Fracture toughness of the femoral midshaft (𝑴𝑷𝒂√𝒎𝒎) 
 
WT OIM 
Control (n=8) Raloxifene (n=7) Control (n=9) Raloxifene (n=11) 
Initiation Toughness* 3.85 ± 0.27 4.10 ± 0.37 2.04 ± 0.20 2.10 ± 0.42 
Maximum  Load Toughness * + 4.51 ± 0.33 4.89 ± 0.38 2.15 ± 0.19 2.24 ± 0.43 
Instability Toughness * 5.22 ± 0.91 5.27 ± 0.94 2.89 ± 0.59 2.56 ± 0.60 
Values are presented as mean ± standard deviation. WT- wild-type; oim-osteogenesis imperfecta. In the 
property column, * indicates a main effect of disease and + indicates a main effect of treatment. 
 
DISCUSSION 
Osteogenesis imperfecta (OI) is a debilitating musculoskeletal condition that presents 
unique treatment challenges due to the combination of bone mass, geometry, and material 
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property deficits. The predominant pharmacological approach for addressing skeletal fragility has 
been to enhance bone mass/geometry and although successful in some regards, the preclinical 
literature clearly shows that adding bone mass is insufficient to completely normalize bone 
mechanical properties [12,13,21-23,25,31,32]. In the current study we demonstrated that 
raloxifene, which is known to improve bone mass/geometry and quality, positively affects oim 
bone through both cellular and non-cellular mechanisms. This suggests a novel approaches for 
offsetting the skeletal fragility of OI. 
Ex vivo mechanical testing of 12 week old female mouse femurs in experiment 1 confirmed 
what numerous other papers have documented -  the presence of significant mechanical deficits 
in oim mice compared to wild-type animals [8,10,21,25,33-35]. To test the hypothesis that 
raloxifene could rescue this mechanical phenotype, contralateral tibia were soaked in raloxifene, 
based on previous studies showing this was sufficient to increase skeletal hydration and 
mechanical properties through non-cellular mechanisms [28]. Soaking produced minimal effects 
on ultimate load or stiffness, but significant main effects on total displacement and energy to 
fracture (Figure 1 and Table 1). This is consistent with our previous work showing that raloxifene 
exposure mainly affects post-yield properties [28,36]. These data provide evidence that oim bone, 
like normal bone, can be positively affected by raloxifene through a non-cellular mechanism as 
the previously frozen tissue is void of viable cells. Based on our previous work we hypothesize 
that these beneficial effects within the matrix are the result of alterations in hydration.  Hydration 
is known to play a key role in mechanical properties [37-39] and is modulated both in vitro and in 
vivo by raloxifene [28,29].   Unfortunately, hydration was not assessed in these bones due to 
technical challenges of working with such small amounts of tissue in the mouse bone.  Future 
work should aim to assess hydration properties with and without interventions in pre-clinical 
models and hydration in patients through non-invasive methods [40,41].  
 The encouraging results from the soaking experiment translated to the in vivo experiment 
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in which wild type and oim animals were treated with raloxifene for eight weeks. Much to our 
surprise, nearly half of the vehicle-treated oim animals had fractured femora at the time of sacrifice 
(16 weeks of age). In contrast, only 20% of the femurs in raloxifene-treated animals were fractured 
– representing a statistically significant, and in our opinion clinically meaningful, 58% reduction in 
the incidence of fracture. Spontaneous fractures are described in the homozygous oim mouse 
[10,42], and have been characterized in several studies [42,43,44]. Although we did not count 
fractures at 8 weeks when treatment began, other studies which did characterize femoral fractures 
at 8 weeks of age suggest that between 22% and 27% of bones were fractured [43,44]. These 
numbers are close to the numbers seen in our RAL-treated mice at 16 weeks (6 of 30 bones, 
20%). Assuming that the oim mice allocated to each treatment group had comparable numbers 
of fractures at 8 weeks, this suggests that RAL may have prevented most additional fractures 
which would have occurred during the treatment period. Given that spontaneous fracture is 
exactly the phenotype we are most interested in treating clinically, our finding of significant 
reductions with a pharmacological treatment (raloxifene) represents a novel and exciting result.  
 Our imaging-based assessment of skeletal properties confirm work of others by showing 
oim animals have lower DXA-based BMD and CT-based trabecular bone volume and cortical 
bone area. Eight weeks of raloxifene treatment resulted in higher total body and femoral BMD, 
and higher trabecular bone volume in both genotypes (Figure 3). There were no significant 
interactions for any imaging measure, indicating that raloxifene was similarly effective in both wild-
type and oim animals. Although raloxifene resulted in significantly higher bone mass compared 
to vehicle-treated oim animals, the values remained below those of untreated wild-type animals. 
This is in contrast to work with both bisphosphonates and anti-sclerostin antibody which have 
been shown to normalize bone mass back to wild-type levels in the oim [22,23,42,45] and Brtl/+ 
models of OI [21,25]. Bisphosphonates are a more potent anti-resorptive agent compared to 
raloxifene, and anti-sclerostin antibody is a potent anabolic agent – thus the ability of these agents 
to enhance bone mass to a greater degree than raloxifene is not surprising.  The potential to 
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combine raloxifene with a more potent enhancer of bone mass represents an exciting next step. 
 The mechanical phenotype of oim animals, based on both four-point bending of the tibia 
and fracture mechanics testing of the femur, were consistent with previous work – showing 
reduced values for almost all parameters [8,21-23,25,33,34]. Overall, the effect of in vivo 
raloxifene treatment on the ex-vivo mechanical phenotype was unimpressive (Tables 4 and 5). 
While there was a significant main effect of raloxifene on Kmax load, indicative of a bone that 
necessitates a higher load to propagate an existing crack, this appears mainly driven by wild-type 
animals. The results of our four point bending tests contrast with the fact that there was a 
significant reduction in fracture.  Although we do not have a clear explanation for these contrasting 
results, we present several hypotheses that could be tested in future studies. First, it’s possible 
that the lower number of fractures in raloxifene-treated animals is a spurious result, yet given the 
effects seen in experiment 1, and the previous work with raloxifene, this seems unlikely.  An 
alternative explanation is that the effects observed in the two experiments are unrelated – the in 
vitro experiment changes being due to altered hydration and the in vivo experiment results being 
driven by some other change (altered activity level of mice, small changes in cortical thickness as 
two examples).  This is a plausible explanation as the mechanisms could differ between males 
and females, or the local concentration of drug exposure could be different. 
 Raloxifene is an FDA approved therapy for treatment of post-menopausal osteoporosis. 
It’s efficacy in fracture risk reduction in this patient population is clear, and appears to be due to 
a combination of traditional mechanisms (reduction of bone resorption) [26-28] and non-traditional 
mechanism (altered skeletal hydration) [26-28]. Despite this, there are also notable side effects 
(thrombosis and estrogenic features) that could pose challenges for translation into patients with 
OI (particularly children) [46]. Yet the results of the current study show, for the first time, the 
conceptual framework for a novel approach to treating OI – targeting the collagen matrix with a 
pharmacological agent. Ongoing work in our lab is aimed at developing novel compounds that 
impart benefits to matrix properties without having any estrogen receptor interaction. We 
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hypothesize that such a compound, perhaps combined with an agent that suppresses osteoclast 
activity such as bisphosphonates, could represent a viable treatment regimen that targets both 
bone quantity and quality in OI.  
 There are some limitations of our study. We treated animals that were still actively growing, 
thus all of our effects are due to interactions between drug treatment and growth. We chose this 
timeline to match other OI interventional treatments and to mimic an intervention in children with 
OI. Fracture incidence was not assessed at 8 weeks when the study began and, as such, it is 
possible that the oim treatment groups were unintentionally unbalanced at the start of the study. 
However, the number of fractures in untreated oim mice at 16 weeks of age here (13 or 27 or 
48%) is comparable to the number seen in untreated mice in a previous study at 12 weeks of age 
(53%, [43]). Regardless, future studies will include a baseline measure of fracture prior to 
treatment. We studied only one dose of raloxifene, and only one sex for the in vivo treatment 
study. These are clearly variables that could be modified in future work and it is possible that the 
disparate results in mechanics between experiments 1 and 2 are due to the different sexes or 
drug exposures used for those studies. We chose our in vivo raloxifene dose based on matching 
the mg/kg dose used in humans and the in vitro dose based on our previous work showing efficacy 
– yet we do not know that these provide similar drug exposure to the bone.  While our sample 
size was sufficient to detect significant effects in many parameters, it may be necessary to have 
larger groups in order to detect differences in traditional mechanical properties. Finally, more 
detailed skeletal analyses, such as histological measures and those of bone quality 
(hydration/collagen/mineralization) would have been useful, yet these were beyond the scope of 
this early proof-of-concept study. 
In conclusion, the current study shows beneficial effects of raloxifene exposure to bone 
properties in the setting of OI. Although the direct mechanism is unclear, changes translate to a 
significant reduction in the number of long bone fractures in this animal model of osteogenesis 
imperfecta.  
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EXPERIMENTAL PROCEDURES 
All animal procedures were performed with prior approval from the Indiana University Purdue 
University Science Animal Research Center (SARC) and Indiana University School of Medicine 
Institutional Animal Care and Use Committee (IACUC). 
 
Experiment Design #1: Ex vivo Effects of Raloxifene 
Freshly frozen tibiae from a previous study [8] were used to assess non-cellular effects of 
raloxifene. Paired tibiae from 12 week old homozygous oim (B6C3Fe a/a-Col1a2oim/Col1a2oim; 
n=9) and WT (B6C3FeF1/J a/a; n=15) female mice [10] were incubated at 37C in PBS or 2 µM 
raloxifene supplemented with 1% Pen/Strep for 13 days (solution changed every 2-3 day) as 
previously described [28]. After soaking, the bones were mechanically tested to failure in four-
point bending (9 mm bottom support and 3 mm loading span) at a displacement rate of 0.025 
mm/sec following standard protocols [47]. Bending occurred in the medial-lateral direction with 
the medial side in tension. Samples remained hydrated with PBS while testing. 
 
Experiment Design #2: In vivo Effects of Raloxifene 
Seven week old homozygous oim (B6C3Fe a/a-Col1a2oim/Col1a2oim) and WT 
(B6C3FeF1/J a/a) male mice were obtained from Jackson Laboratory. After one week of 
acclimation, mice were injected 5 days per week for eight weeks with saline vehicle (VEH; n=8 
WT and n=14 oim) or 0.5 mg/kg raloxifene (RAL; n=8 WT and n=15 oim). This dose was chosen 
to approximate the clinical dose on a mg/kg basis and have been used previously in pre-clinical 
studies [29,36]. At 16 weeks of age, the mice were euthanized by CO2 inhalation. Dual-energy X-
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ray absorptiometry (DXA) was performed with the whole body, femur, and L4-L5 vertebrae as 
regions of interest (ROI). Following DXA, the femurs and tibiae were removed, wrapped in saline-
soaked gauze, and stored at -20 °C until analysis. 
 
Microcomputed Tomography (uCT) Analysis of Femurs 
Both femurs from each mouse were scanned while hydrated at a 9.8 µm voxel size using 
a Bruker 1172 uCT system (176 mA, 0.5 mm Aluminum filter). Calibration was performed daily 
using two hydroxyapatite phantoms to convert grayscale values into g/cm3. Images were then 
reconstructed for cortical and trabecular analyses. The projection scans of both left and right 
femora were used to assess the incidence of fracture. Three of the four authors examined the 
projection views and scored them as intact or fractured. When projection images were ambiguous 
of fracture, the reconstructed images were used for determination. Bones with fractures were 
excluded from further CT and mechanical analysis. For cortical analysis, a standard ROI was 
analyzed at 40% of the bone’s length measured from the distal end. At this location, seven 
transverse slices were analyzed (approximately 69 µm in length). Tissue mineral density (TMD) 
was calculated using vendor-supplied software (CTan). A standard binary threshold was then 
applied to the slices and geometric properties were calculated using a custom MATLAB code, as 
previously described [48]. Trabecular analysis was performed in the distal metaphysis on an ROI 
defined as 10% of the total bone length, beginning at the proximal end of the distal growth plate 
and extending proximally. Within that region, cancellous bone was segmented from the cortical 
shell using a custom MATLAB script. Geometric parameters were determined using vendor-
supplied software (CTan). 
 
Fracture Toughness Testing of Femurs 
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 Following uCT, fracture toughness of the femurs was assessed following a linear elastic 
fracture mechanics approach [33,49]. Due to the incidence of fracture in the oim groups, a 
combination of left and right femurs was used. However, only one bone was tested per mouse. A 
notch was made on the anterior surface of the femur using a scalpel blade pasted with a 100 µm 
diamond suspension. The notch entered the medullary cavity, but did not extend past the mid-
point of the bone. Notched femurs were then tested to failure in 3 point bending at 0.001 mm/sec 
with the loading point located directly above the notch. Following testing, bones were cleaned of 
marrow and dehydrated through graded ethanol (70-100%) for scanning electron microscopy 
(SEM). SEM images of the fracture surface were used to obtain crack angles which, in conjunction 
with geometric properties from the uCT data, allowed for the calculation of fracture instability at 
5% secant (Kinit), maximum load (Kmax load), and failure load (Kinst). 
 
Whole Bone Mechanical Testing of Tibiae 
 Prior to whole bone mechanical testing, the left tibia from each mouse was scanned by 
uCT (16.8 µm voxel size) using methods described above. A lower resolution was used for the 
tibia as only cortical properties were of interest to allow for normalization of force-displacement 
data. The bones were then tested to failure in four-point bending as described in experiment 1. 
Following fracture, the location of the site of fracture was recorded and the µCT data were used 
to obtain geometric properties at the fracture location. A 5% loss in secant stiffness was used to 
define the yield point. Force-displacement data were normalized to stress-strain using standard 
beam bending equations and the data were analyzed using a custom MATLAB script, as 
previously described [48].  
 
Statistical Analysis 
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 All data were checked for assumptions of normality and homogeneity of variance, and 
violations were corrected using transformations. For in vitro soaking experiments, statistics 
consisted of a repeated measures ANOVA to observe within-subject (main effect of treatment) 
and between-subject (main effect of disease) results (p<0.05). In the case of interactions, pairwise 
t-tests (paired for effect of treatment; unpaired for effect of disease) were performed and a 
Bonferroni correction was applied (p<0.0125 was considered significant). For the in vivo treatment 
experiments, a two-Way ANOVA was performed to assess the main effects of disease and 
treatment (p<0.05 was considered significant). Because of the staggered arrival of animals in our 
facility, the date of arrival was blocked as a nuisance factor. For the fracture assessment data, a 
Fisher’s Exact Test was used to compare the proportion of fractures in oim VEH versus RAL as 
none of the WT mice exhibited fractures. 
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